Fenton chemistry and oxidative stress mediate the toxicity of the β‐amyloid peptide in a Drosophila model of Alzheimer’s disease

Abstract

The mechanism by which aggregates of the β‐amyloid peptide (Aβ) mediate their toxicity is uncertain. We show here that the expression of the 42‐amino‐acid isoform of Aβ (Aβ 1–42 ) changes the expression of genes involved in oxidative stress in a Drosophila model of Alzheimer’s disease. A subsequent genetic screen confirmed the importance of oxidative stress and a molecular dissection of the steps in the cellular metabolism of reactive oxygen species revealed that the iron‐binding protein ferritin and the H 2 O 2 scavenger catalase are the most potent suppressors of the toxicity of wild‐type and Arctic (E22G) Aβ 1–42 . Likewise, treatment with the iron‐binding compound clioquinol increased the lifespan of flies expressing Arctic Aβ 1–42 . The effect of iron appears to be mediated by oxidative stress as ferritin heavy chain co‐expression reduced carbonyl levels in Aβ 1–42 flies by 65% and restored the survival and locomotion function to normal. This was achieved despite the presence of elevated levels of the Aβ 1–42 . Taken together, our data show that oxidative stress, probably mediated by the hydroxyl radical and generated by the Fenton reaction, is essential for Aβ 1–42 toxicity in vivo and provide strong support for Alzheimer’s disease therapies based on metal chelation.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 51

1. 1.

   Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci. 2004;24:565-575.

   Not in our library10.1523/jneurosci.4042-03.2004

2. 2.

   Alamdari DH, Kostidou E, Paletas K, Sarigianni M, Konstas AG, Karapiperidou A, Koliakos G. High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Free Radic. Biol. Med. 2005;39:1362-1367.

   Not in our library10.1016/j.freeradbiomed.2005.06.023

3. 3.

   Anderson PR, Kirby K, Hilliker AJ, Phillips JP. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum. Mol. Genet. 2005;14:3397-3405.

   Not in our library10.1093/hmg/ddi367

4. 4.

   Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000;25:25-29.

   Not in our library10.1038/75556

5. 5.

   Botella JA, Ulschmid JK, Gruenewald C, Moehle C, Kretzschmar D, Becker K, Schneuwly S. The Drosophila carbonyl reductase sniffer prevents oxidative stress-induced neurodegeneration. Curr. Biol. 2004;14:782-786.

   Not in our library10.1016/j.cub.2004.04.036

6. 6.

   Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 1995;56:1151-1171.

   Not in our library10.1016/0024-3205(95)00055-b

7. 7.

   Bush AI. The metallobiology of Alzheimer’s disease. Trends Neurosci. 2003;26:207-214.

   Not in our library10.1016/s0166-2236(03)00067-5

8. 8.

   Cao W, Song HJ, Gangi T, Kelkar A, Antani I, Garza D, Konsolaki M. Identification of novel genes that modify phenotypes induced by Alzheimer’s β-amyloid overexpression in Drosophila. Genetics. 2008;178:1457-1471.

   Not in our library10.1534/genetics.107.078394

9. 9.

   Chen Z, Duan RS, Lepecheur M, Paly E, London J, Zhu J. SOD-1 inhibits FAS expression in cortex of APP transgenic mice. Apoptosis. 2005;10:499-502.

   Not in our library10.1007/s10495-005-1879-y

10. 10.

    Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron. 2001;30:665-676.

    Not in our library10.1016/s0896-6273(01)00317-8

11. 11.

    Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, Gubb DC, Lomas DA. Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer’s disease. Neuroscience. 2005;132:123-135.

    Not in our library10.1016/j.neuroscience.2004.12.025

12. 12.

    Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005;280:17294-17300.

    Not in our library10.1074/jbc.m500997200

13. 13.

    Dikalov SI, Vitek MP, Mason RP. Cupric-amyloid beta peptide complex stimulates oxidation of ascorbate and generation of hydroxyl radical. Free Radic. Biol. Med. 2004;36:340-347.

    Not in our library10.1016/j.freeradbiomed.2003.11.004

14. 14.

    Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta. 1996;1275:161-203.

    Not in our library10.1016/0005-2728(96)00022-9

15. 15.

    Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. 1999a;38:7609-7616.

    Not in our library10.1021/bi990438f

16. 16.

    Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 1999b;274:37111-37116.

    Not in our library10.1074/jbc.274.52.37111

17. 17.

    Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.

    Not in our library10.1093/nar/gng015

18. 18.

    Jo DG, Lee JY, Hong YM, Song S, Mook-Jung I, Koh JY, Jung YK. Induction of pro-apoptotic calsenilin/DREAM/KChIP3 in Alzheimer’s disease and cultured neurons after amyloid-beta exposure. J. Neurochem. 2004;88:1570.

    Not in our library10.1111/j.1471-4159.2004.02159.x

19. 19.

    Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron. 2003;37:899-909.

    Not in our library10.1016/s0896-6273(03)00126-0

20. 20.

    Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004;279:46363-46366.

    Not in our library10.1074/jbc.c400260200

21. 21.

    Khan A, Dobson JP, Exley C. Redox cycling of iron by Abeta42. Free Radic. Biol. Med. 2006;40:557-569.

    Not in our library10.1016/j.freeradbiomed.2005.09.013

22. 22.

    Kienlen-Campard P, Miolet S, Tasiaux B, Octave JN. Intracellular amyloid-beta 1–42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis. J. Biol. Chem. 2002;277:15666-15670.

    Not in our library10.1074/jbc.m200887200

23. 23.

    Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 1994;269:17386-17389.

    Not in our library

24. 24.

    Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA. 1998;95:6448-6453.

    Not in our library10.1073/pnas.95.11.6448

25. 25.

    Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002;418:291.

    Not in our library10.1038/418291a

26. 26.

    Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol. Aging. 1997;18:457-461.

    Not in our library10.1016/s0197-4580(97)00108-5

27. 27.
    Systematic In Vivo Analysis of the Intrinsic Determinants of Amyloid β Pathogenicity · 2007

    No notice
28. 28.

    Lynch SM, Boswell SA, Colon W. Kinetic stability of Cu/Zn superoxide dismutase is dependent on its metal ligands: implications for ALS. Biochemistry. 2004;43:16525-16531.

    Not in our library10.1021/bi048831v

29. 29.

    Maier CM, Chan PH. Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscientist. 2002;8:323-334.

    Not in our library10.1177/107385840200800408

30. 30.

    Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol. Aging. 1998;19:33-36.

    Not in our library10.1016/s0197-4580(98)00009-8

31. 31.

    Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 2005;58:730-735.

    Not in our library10.1002/ana.20629

32. 32.

    Missirlis F, Hu J, Kirby K, Hilliker AJ, Rouault TA, Phillips JP. Compartment-specific protection of iron-sulfur proteins by superoxide dismutase. J. Biol. Chem. 2003;278:47365-47369.

    Not in our library10.1074/jbc.m307700200

33. 33.

    Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002a;287:3230-3237.

    Not in our library10.1001/jama.287.24.3230

34. 34.

    Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Vitamin E and cognitive decline in older persons. Arch. Neurol. 2002b;59:1125-1132.

    Not in our library10.1001/archneur.59.7.1125

35. 35.

    Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat. Neurosci. 2001;4:887-893.

    Not in our library10.1038/nn0901-887

36. 36.

    Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001;60:759-767.

    Not in our library10.1093/jnen/60.8.759

37. 37.

    Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005;352:2379-2388.

    Not in our library10.1056/nejmoa050151

38. 38.

    Phillips JP, Tainer JA, Getzoff ED, Boulianne GL, Kirby K, Hilliker AJ. Subunit-destabilizing mutations in Drosophila copper/zinc superoxide dismutase: neuropathology and a model of dimer dysequilibrium. Proc. Natl Acad. Sci. USA. 1995;92:8574-8578.

    Not in our library10.1073/pnas.92.19.8574

39. 39.

    Refolo LM, Sambamurti K, Efthimiopoulos S, Pappolla MA, Robakis NK. Evidence that secretase cleavage of cell surface Alzheimer amyloid precursor occurs after normal endocytic internalization. J. Neurosci. Res. 1995;40:694-706.

    Not in our library10.1002/jnr.490400515

40. 40.

    Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003;60:1685-1691.

    Not in our library10.1001/archneur.60.12.1685

Cited by papers we hold 5

• The essential elements of Alzheimer’s disease · 2021
  No notice
• Iron in Neurodegeneration – Cause or Consequence? · 2019
  No notice
• Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine · 2013
  Corrected
• Drosophila melanogaster as a model organism for Alzheimer’s disease · 2013
  No notice
• A delicate balance: Iron metabolism and diseases of the brain · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.